NCT07400926Recruiting

Observational Trial of the Updated Inserter for the Travoprost Intracameral Implant 75mcg

Glaukos Corporation

Start Date

12/17/2025

Completion Date

7/1/2026

Summary

Clinical in-use observational trial to evaluate the updated inserter for the Travoprost Intracameral implant using the updated inserter (Model G2-TRIO)

Detailed Description

The objective of this study is to evaluate the administration of the Travoprost intracameral implant using the updated inserter (Model G2-TRIO)

Eligibility Criteria

Age Range: 18 years to No maximum

Inclusion Criteria: * Diagnosis of Open-angle glaucoma * 18 years of age or older Exclusion Criteria: * Subject who is breast-feeding or pregnant

Interventions

COMBINATION_PRODUCT

Travoprost

Interested in This Trial?

Contact the trial locations directly using the information below to learn more about enrollment.

Expressing interest lets you review the study and consent before we connect you with the research site.

Conditions

Open Angle Glaucoma (OAG)Ocular Hypertension (OH)

Locations

Glaukos Investigative Site

Kenosha, Wisconsin 53140

United States

Run studies, or work at a research site?

Corterve helps sites and sponsors reach patients who are looking for trials. It does not determine eligibility and does not promise an enrolment outcome.

For sponsors, CROs and sites

What Corterve sells to organisations, and the anti-kickback constraints it works within.

Services and published prices

Lay summaries for EU CTR Annex V, pre-screen filtration, recruitment-creative regulatory operations, feasibility reporting.

For research sites

One published licence rate, the same for every site, and the fees a site is never charged.